South Korea To Join U.S., U.K., Japan With New Bird Flu Vaccine
This article was originally published in PharmAsia News
A South Korean veterinary professor says he has developed a vaccine for humans to guard against avian influenza to add to those developed in three other countries. The Chungnam National University professor said he developed the CNUK-H5N1-08-01 vaccine with a gene recombination technique to reduce the H5N1 toxicity. Along with the United States, the United Kingdom and Japan, South Korea now can produce a vaccine for people immune to existing vaccines. (Click here for more
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.